At the recent Heart Rhythm 2019 meeting, we spoke with Dr Douglas Packer (Cardiac Electrophysiologist, Cardiologist and Internist, Mayo Clinic Hospital, Saint Mary’s Campus, Rochester, MN, USA) about the CABANA trial and the limitations of current drug therapy for atrial fibrillation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Douglas Packer has provided consulting services for Abbott, Biosense Webster Inc., Biotronik, Boston Scientific, CardioFocus, Johnson & Johnson, MediaSphere Medical, LLC, Medtronic, St Jude Medical, Siemens, SigNum Preemptive Healthcare, Inc., Spectrum Dynamics and Thermedical. He receives research funding from Abbott, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic, NIH, Roberston Foundation, St Jude Medical, Siemens and Thermedical. He has financial interests in mapping technology through St Jude Medical and Mayo Clinic, has equity in External Beam Ablation Medical Devices and receives royalties from Wiley & Sons, Oxford and St Jude Medical.
Questions:
1. What are the limitations of current drug therapy for atrial fibrillation? (0:09)
2. What was the rationale behind the Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) trial? (0:58)
3. What were the outcomes of the CABANA trial? (1:39)
4. What were the limitations of the study? (5:04)
5. What impact do you think the results will have on the management of atrial fibrillation? (6:01)
6. What do you have planned for the future? (7:53)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
